Editors Choice Article | Rational Design of Colchicine Derivatives as anti-HIV Agents via QSAR and Molecular Docking

Journal Name: Medicinal Chemistry

Author(s): Apilak Worachartcheewan*, Napat Songtawee, Suphakit Siriwong, Supaluk Prachayasittikul*, Chanin Nantasenamat, Virapong Prachayasittikul.

 

02

Background: Human immunodeficiency virus (HIV) is an infective agent that causes an acquired immunodeficiency syndrome (AIDS). Therefore, the rational design of inhibitors for preventing the progression of the disease is required.

Objective: This study aims to construct quantitative structure-activity relationship (QSAR) models, molecular docking and newly rational design of colchicine and derivatives with anti-HIV activity.

Methods: A data set of 24 colchicine and derivatives with anti-HIV activity were employed to develop the QSAR models using machine learning methods (e.g. multiple linear regression (MLR), artificial neural network (ANN) and support vector machine (SVM)), and to study a molecular docking.

Results: The significant descriptors relating to the anti-HIV activity included JGI2, Mor24u, Gm and R8p+ descriptors. The predictive performance of the models gave acceptable statistical qualities as observed by correlation coefficient (Q2) and root mean square error (RMSE) of leave-one out cross-validation (LOO-CV) and external sets. Particularly, the ANN method outperformed MLR and SVM methods that displayed LOO−CV 2 Q and RMSELOO-CV of 0.7548 and 0.5735 for LOOCV set, and Ext 2 Q of 0.8553 and RMSEExt of 0.6999 for external validation. In addition, the molecular docking of virus-entry molecule (gp120 envelope glycoprotein) revealed the key interacting residues of the protein (cellular receptor, CD4) and the site-moiety preferences of colchicine derivatives as HIV entry inhibitors for binding to HIV structure. Furthermore, newly rational design of colchicine derivatives using informative QSAR and molecular docking was proposed.

Conclusion: These findings serve as a guideline for the rational drug design as well as potential development of novel anti-HIV agents. To read out more, please visit: http://www.eurekaselect.com/165617/article

Author: Bentham Science

Bentham Science is a leading publishing company in the field of science, technology, and medicine. Established in 1992, the company has grown to become one of the most reputable and respected publishers in the scientific community. Bentham Science publishes more than 100 online and print journals, along with over 300 eBooks and over 2000 reference works. These publications cover a wide range of topics, including pharmaceutical sciences, biotechnology, chemistry, engineering, and more. In addition to its publications, Bentham Science also provides various services to the scientific community, including manuscript editing, article formatting, and language polishing. The company is committed to promoting scientific research and discovery by providing a platform for researchers to share their work with a wider audience. Bentham Science's reputation for excellence is built on a commitment to quality, integrity, and innovation. Its editorial team consists of experts in their respective fields who ensure that all publications are rigorously peer-reviewed and meet the highest standards of scientific accuracy. Overall, Bentham Science is an invaluable resource for scientists, researchers, and academics who are looking to stay up-to-date on the latest developments in their fields. With its wide range of publications and commitment to quality, the company is poised to remain a leader in the scientific publishing industry for years to come.

Leave a comment